ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Operationalizing Human Immunodeficiency Virus Cure-related Trials with Analytic Treatment Interruptions During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic: A Collaborative Approach.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Trial
- Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research.Current opinion in HIV and AIDS · 2025Review
- Lessons Learned in Eliciting Systematic Participant Perspectives in a Combination HIV Cure Research Trial.AIDS research and human retroviruses · 2025Article
- Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption.The Journal of infectious diseases · 2025Article
- Evaluating the psychosocial experiences of participants in HIV cure research before, during, and after analytical treatment interruptions: A longitudinal qualitative study in the United States.Social science & medicine (1982) · 2025Article
- Impact of an analytical treatment interruption on partners and family members of trial participants in Durban, South Africa: a qualitative study.Frontiers in public health · 2025Article
- Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk.Journal of virus eradication · 2024Article
- Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.HIV research & clinical practice · 2024Article
- Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.HIV research & clinical practice · 2023Article
- Critical considerations for public engagement in stem cell-related research.Stem cell reports · 2023Article
- Participant experiences using novel home-based blood collection device for viral load testing in HIV cure trials with analytical treatment interruptionsHIV research & clinical practice · 2022Article
- Community HIV clinicians' perceptions about HIV cure-related research in the Northwestern United States.HIV research & clinical practice · 2022Article
- "It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States.BMC public health · 2022Article
- Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States.BMC medical ethics · 2022Article
- SARS-CoV-2 Booster Vaccination for Participants in "HIV Cure"-Related Clinical Trials.Journal of acquired immune deficiency syndromes (1999) · 2022Article
- Bringing social context into global biomedical HIV cure-related research: An urgent call to action.Journal of virus eradication · 2022Article
- Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States.Journal of personalized medicine · 2022Article
- Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19.Journal of the International AIDS Society · 2022Article
- Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.Current HIV/AIDS reports · 2021Review
- Ethics of HIV cure research: an unfinished agenda.BMC medical ethics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Efforts to recognize and minimize the risk to study participants will be necessary to safely and ethically resume scientific research in the context of the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. These efforts are uniquely challenging in the context of human immunodeficiency virus (HIV) cure clinical trials, which often involve complex experimental therapy regimens and perhaps analytic treatment interruption, in which participants pause antiretroviral therapy. In this viewpoint, we discuss our approach to reopening an HIV cure trial in this context, with a focus on key considerations regarding study design, informed consent and participant education, and study implementation. These recommendations might be informative to other groups seeking to resume HIV cure research in settings similar to ours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.